Introduction
============

Tissue adhesives such as N-butyl-2-cyanoacrylate glue, are highly effective in managing bleeding from gastric fundal varices (GOV-2/IGV-1) with most series reporting rates of \> 90 % for achieving hemostasis [@JR1056-1] . However, there have been a number of reports of systemic embolization of the glue material post-injection, including at least one report of fatal pulmonary embolism [@JR1056-2] [@JR1056-3] . It is also difficult to administer, resulting in a damaged endoscope if not prepared properly. With such relatively low number of patients presenting annually with upper gastrointestinal bleeding secondary to gastric fundal varices, it is unsurprising that there is uncertainty amongst endoscopists when it comes to administering glue [@JR1056-4] .

Human thrombin can also be used to treat bleeding from gastric fundal varices. It is easy to administer and does not appear to be associated with the same embolic complications as glue, and therefore provides an effective and safe alternative. However, the rates of re-bleeding are often higher, ranging from 7 % to 50 % among series, and given the paucity of data in follow-up and eradication studies, it is often only recommended as bridging therapy to a more definitive treatment such as glue, trans-jugular intrahepatic portosystemic shunt (TIPS), balloon retrograde trans-venous obliteration (BRTO), or transplantation [@JR1056-1] [@JR1056-5] .

Endoscopic ultrasound (EUS) can assess variceal blood flow and looks to be a useful tool for evaluation, treatment, and estimation of recurrent bleeding potential of gastric fundal varices [@JR1056-6] [@JR1056-7] [@JR1056-8] . There are a number of case reports and studies describing its successful utilization in management of gastric fundal varices, using glue, coils or a combination of the two [@JR1056-9] [@JR1056-10] [@JR1056-11] [@JR1056-12] [@JR1056-13] [@JR1056-14] [@JR1056-15] [@JR1056-16] . Although there is a case report in the literature on EUS-guided thrombin therapy for ectopic varices, to our knowledge nothing currently exists on its use in gastric fundal varices [@JR1056-17] . We present the results of a series of patients treated with this method.

Patients and methods
====================

Study design
------------

All patients treated with EUS-guided thrombin injection were included in the report, with the earliest recorded treatment taking place in October 2013 and the latest in January 2017. Patients initially selected for treatment with EUS-guided thrombin injections were on elective varices surveillance lists with persistent gastric fundal varices despite previous attempts at endoscopic eradication. After procedural success with EUS-guided thrombin injection was observed in the elective surveillance group, it was then also attempted in patients admitted with active bleeding. Glue is not used in our center for bleeding gastric fundal varices due to the complications outlined above, and therefore, experience with it is limited. As neither TIPS nor BRTO are readily available in our center, human thrombin injection without EUS guidance is often our initial treatment of choice to achieve hemostasis, with radiological intervention being reserved for refractory cases. Informed consent was obtained in all instances.

During the study period, eight patients were treated: three for active variceal hemorrhage and five electively for persistent fundal varices. In the latter group four of five of the patients were also receiving treatment with non-selective beta blockers (NSBBs), with the remaining patient unable to take such medication due to underlying heart block. All procedures were performed by one endosonographer skilled in advanced endoscopic techniques. Outcomes evaluated were as follows:

-   Successful achievement of hemostasis, defined as no further episodes of overt bleeding or need for further therapeutic endoscopy/radiological intervention within 3 months;

-   Endosonographic evidence of variceal obliteration during thrombin administration;

-   Measurement in international units (IU) of the dose of thrombin required to produce variceal obliteration; and

-   Incidence of procedure-related adverse events (AEs).

. Performing the procedure
--------------------------

A linear EUS endoscope was placed at the gastroesophageal junction and the fundal varices identified. If a "feeding vessel" could be identified, it was specifically targeted for thrombin therapy, otherwise the largest, most accessible varix/varices were selected and injected under direct ultrasound guidance using a standard 22-gauge EUS needle. Thrombin was either reconstituted with 0.9 % sodium chloride as a 1000 IU/5 mL solution or 2500 IU/5 mL solution dependent on the formulation available to the endoscopy department without use of the gelatine matrix provided. Thrombin was injected either until no further flow was identified on color Doppler (at which point the varix was considered obliterated), or until a maximum of 10 000 IU of thrombin was administered. The procedure is demonstrated in our video, which showcases three cases from our study ( [Video 1](#ME1056-1){ref-type="media"} ).

Endoscopic surveillance for patients undergoing thrombin injection electively was booked at 3 or 6 months (depending on the burden of variceal disease and the endoscopist's clinical judgement) and then annually thereafter depending on procedural success.

Endoscopic surveillance for patients successfully treated in the active variceal hemorrhage was booked at 4 weeks initially, with further follow-up at 3 and 12 months if endosonographic obliteration was achieved.

Results
=======

All patients included in the study had established cirrhotic liver disease with three patients having co-existing portal vein thrombosis. For ease of reference, we present the demographic data in   [Table 1](#TB1056-1){ref-type="table"} . Please note that other than being classified as "active variceal hemorrhage" and "elective prevention," the patients are presented in no particular order and do not necessarily correlate to the cases demonstrated in the video.

###### Participant demographic data.

  **Patient**               **Age**   **Sex**   **Diagnosis**                                       **PVT**   **Child Pugh Score**   **MELD**   **Sarin classification**   **Thrombin dose**   **Obliteration successful?**             **Did OV require treatment?**
  ------------------------- --------- --------- --------------------------------------------------- --------- ---------------------- ---------- -------------------------- ------------------- ---------------------------------------- -------------------------------
  **Active hemorrhage**                                                                                                                                                                                                                 
  1                         40        M         ALD [1](#FN1056-1){ref-type="table-fn"}             No        11 (C)                 22         GOV-2                      10 000 IU           No                                       No (grade 1; no red sign)
  2                         64        M         NAFLD                                               Yes        6 (A)                 10         GOV-2                        7500 IU           Yes                                      EBL
  3                         68        M         ALD [1](#FN1056-1){ref-type="table-fn"}             No         8 (B)                 12         IGV-1                        4250 IU           Yes                                      --
  **Elective prevention**                                                                                                                                                                                                               
  4                         67        M         NAFLD                                               No         5 (A)                  7         IGV-1                        1000 IU           Yes                                      --
  5                         70        M         ALD + NAFLD                                         Yes        7 (B)                 10         IGV-1                         600 IU           Yes                                      --
  6                         58        M         ALD + HCV                                           No         6 (A)                  9         IGV-1                       5000 IU            No [2](#FN1056-2){ref-type="table-fn"}   --
  7                         72        F         NAFLD                                               No         6 (A)                 11         GOV-2                       5000 IU            Yes                                      No (grade 1; no red sign)
  8                         55        M         Cryptogenic cirrhosis and myelofibrosis (JAK2 + )   Yes        7 (B)                  8         GOV-2                       1000 IU            Yes                                      EBL

PVT, portal vein thrombosis; MELD, model for end-stage liver disease; OV, esophageal varices; ALD, alcoholic liver disease; NAFLD, non-alcoholic fatty liver disease; HCV, Hepatitis C virus; EBL, endoscopic band ligation.

Patients with ongoing high levels of alcohol consumption.

Obliteration noted initially after 5000 IU of thrombin, but on future surveillance, flow within the variceal network had returned.

Active variceal hemorrhage
--------------------------

Among those receiving EUS-guided thrombin therapy for active variceal hemorrhage, two of three patients (67 %) had an excellent response to therapy with successful hemostasis and complete endosonographic variceal obliteration with 4250 IU and 7500 IU, respectively. In addition, there has been no recorded incidence of re-bleeding with a mean follow-up time of 100 days.

In one of three patients (33 %), therapy was unsuccessful and the patient went on to have further bleeding. During the procedure 10 000 IU of thrombin was administered with no significant alteration in variceal blood flow, therefore, the procedure was abandoned and the decision was made to refer for urgent TIPS (Case 3 in [Video 1](#ME1056-1){ref-type="media"} ). Unfortunately, the patient subsequently discharged himself against advice and died from a further variceal hemorrhage at a later date. That was the only death recorded in the study and we believe that given the circumstances, it was essentially unavoidable and unrelated to use of thrombin.

There were no direct procedure-related AEs observed.

Elective prevention
-------------------

Complete endosonographic variceal obliteration was noted in five of five patients (100 %) undergoing EUS-guided thrombin therapy for prevention of future bleeding. The dose of thrombin used ranged from 600 IU to 5000 IU (mean 2520 IU) and none of the patients have had further bleeding with a mean follow-up time of 723 days. In four of five patients (80 %), gastric fundal varices have remained eradicated on surveillance endoscopy and no further treatment has been required. In one of five patients (20 %) surveillance endoscopy revealed persistent variceal disease despite previously documented procedural success. Due to a booking error, that patient had his initial surveillance endoscopy at 8 months as opposed to the 3 months intended by the endoscopist. There were no direct procedure-related complications observed.

Discussion
==========

Variceal hemorrhage only accounts for around 10 % of admissions for acute upper gastrointestinal bleeding, with up to one-third of those being secondary to gastric varices [@JR1056-4] [@JR1056-18] . Although bleeding from gastric varices tends to occur less frequently, it is often more severe and associated with a higher rate of mortality than bleeding from esophageal varices [@JR1056-19] . Although the reasons for this are multi-factorial, a significant contributing factor has to be the difficulty in administering endoscopic treatment.

EUS-guided thrombin injection appears to have advantages over standard administration as it allows for direct visualization and targeting of the variceal network. In our case series using human thrombin, only one of eight patients (13 %) had further bleeding post-treatment which is potentially very promising given its ease of administering the injections. Human thrombin works through direct clot formation within the vessel, thereby obstructing blood flow and resulting in hemostasis in 70 % to 100 % of cases of gastric variceal bleeding [@JR1056-1] . The reasons behind previously reported high re-bleeding rates therefore are unclear when compared with the results from our study; however, we would postulate that submucosal (as opposed to intra-variceal) injection and insufficient thrombin load may constitute a significant proportion. We were able to demonstrate that larger doses of thrombin are required when treating active bleeding to achieve endosonographic variceal obliteration, while earlier studies used much lower doses of thrombin on average (1500 -- 2000 IU), potentially suggesting an inadequate reduction in variceal blood flow when thrombin is injected without EUS guidance [@JR1056-1] [@JR1056-20] . In support of this theory, human thrombin is routinely used to successfully control bleeding from pseudo-aneurysm formation after cardiac catheterization, which is normally performed under direct visualization with ultrasound guidance and has a cumulative success rate of 97 % [@JR1056-21] .

In our "elective prevention" group, one of our patients seemed to have restoration of blood flow on surveillance endoscopy despite previously observed endosonographic obliteration. This is interesting and might presumably be due to the body's natural fibrinolytic pathways breaking down the clot over time. In this case, the surveillance endoscopy was unintentionally performed at 8 months and raises questions as to what the optimal time for endoscopic surveillance should be. This patient had a further EUS-guided procedure with thrombin administration, but on this occasion, there was no alteration in variceal flow demonstrated. Given the disappointing response to treatment, further attempts at endoscopic eradication were abandoned with plans to refer for TIPSS in the event of future bleeding. This decision was ultimately made by the patient's hepatologist, and it is important to emphasize that should the expertise be available, treatment with glue or other EUS-guided treatments (such as coil insertion) could be considered prior to interventional radiology.

During the study period the optimal time for repeat endoscopy was largely unknown and therefore the surveillance protocol was designed somewhat pragmatically dependent on the endoscopist's clinical judgement. Currently it is our local policy to perform follow up at 1, 3 and 12 months post-treatment provided endosonographic obliteration is observed, however, more research needs to be performed before we can make specific recommendations on endoscopic surveillance.

There are clear limitations to our study. First, the numbers are small and therefore the study is insufficiently powered to draw any firm conclusions regarding safety or efficacy of the proposed treatment. The data have not been collected prospectively, and therefore the surveillance endpoints among patients differ according to when they were first treated. It would also have been useful to have included a comparison group of patients, either receiving "blind" thrombin as per our department's standard operating practice or perhaps more helpfully against cyanoacrylate glue, given that it remains the recommended first-line modality for endoscopic treatment of gastric fundal varices. In cases in which a "feeding" vessel had been identified, it would have been helpful to specifically document this as it may well account for some of the variations seen in the amounts of thrombin required for obliteration and degree of procedural success [@JR1056-22] . Finally, in patients receiving EUS-guided thrombin therapy electively, it is unclear whether absence of further bleeding was the result of endosonographic variceal obliteration or NSBB use, particularly as one of the patients had persistent varices at surveillance but did not re-bleed, and that would need to be factored in to any studies going forward.

Conclusions
===========

The results of our study are promising and we would certainly advocate a role for the use of EUS in management of gastric fundal varices. As a general measure it allows for direct visualization and targeting of injection therapy, provides a good estimate of when treatment has been successful, and facilitates early planning for further procedures, should endosonographic variceal obliteration be unsuccessful.

Use of EUS-guided thrombin injection was effective in the patients in our case series, resulting in a lower risk of re-bleeding than that previously seen with standard thrombin administration and cyanoacrylate glue. Given the difficulties and adverse effects associated with tissue adhesives, we hope that thrombin will provide a viable alternative to use of cyanoacrylate glue as first-line endoscopic therapy in the future, but more work needs to be done in this area in order to draw any firm conclusions. We would suggest a prospective evaluation of a larger cohort going forward.
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